Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Trends, and Forecast 2019 - 2027

  • Published On : Aug 2019 |
  • Pages : 150 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Anti-Suicide Drugs – Beacon Light of Life on the Horizon

Depression is one of the major healthcare burdens worldwide leading to lower productivity and in severe cases leading to suicidal tendencies. Anti-depressant and anti-psychotic drugs are especially high in demand during economic crisis and social negligence. These drugs also serve as a therapy for preventing suicidal thoughts and attempts. However, overdose of these drugs can be fatal and therefore, needs to be administered under the direction of a physician. Extensive research related to suicide treatment is expected to provide a better solution to the global population during the latter half of the forecast period (2019-2027). This would improve the outlook of global anti-suicide drugs market and would help in reducing deaths due to suicide.

The global anti-suicide drugs market was valued at US$ 3,818.1 million in 2018 and is expected to witness a moderate CAGR of 4.1% during the forecast period (2019 – 2027).

Figure 1. Global Anti-Suicide Drugs Market, Drug Pipeline Snapshot

  Anti-suicide Drugs Market | Coherent Market Insights

Source: Coherent Market Insights Analysis (2017)

Anti-Suicide Drugs Market to be on High Growth Trajectory Post Launch of Anti-Suicidal Drug

NeuroRx Pharma has developed a novel anti-suicidal product Cyclurad (D-cycloserine and Lurasidone) which is indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. The estimated commercialization of the drug post-2020 is expected to be a major breakthrough innovation for the anti-suicide drugs market. Moreover, introduction of other such novel drugs for suicide would augment the anti-suicide market growth. People with major depressive disorder and risk for suicide would greatly benefit from such novel drug therapies.

Furthermore, increase in research studies for ketamine, an anesthetic drug in reducing suicidal thoughts in depressed people may also exhibit a significant growth in the market. For instance, in December 2017, a researcher from the Columbia University Medical Center in the U.S. found that administration of low-dose ketamine had a significant results in reduction of suicidal thoughts within 24 hours among 80 depressed adults. Such treatment offers a promising treatment for rapid relief of suicidal thoughts in depressed people.

High Suicidal Rates to Contribute Towards the Positive Anti-Suicide Drugs Market Outlook

According to the World Health Organization (WHO), suicide accounted for 1.4% of the total deaths worldwide in 2012, accounting for around 800 thousand deaths each year. Russia, India, Republic of Korea, Guyana, Lithuania, Sri Lanka, Hungary, Kazakhstan, and Japan are among the nations with high suicidal rates as per the WHO 2012 data. Emerging nations therefore possess immense opportunity for anti-suicidal drugs. However, being the first ever oral anti-suicidal therapeutic drug, companies are likely to capture the anti-suicide drugs market in developed regions such as North America and Western Europe. This mainly due to rapid adoption of new therapies and accessibility to healthcare facilities in these regions as compared to emerging economies.

Anti-Suicide Drugs Market to Gain Initial Traction in Developed Economies

Major players operating in the global anti-suicide drugs market include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson. High healthcare expenditure in developed economies of North America and Europe is responsible for a higher market size of anti-suicidal drugs in these regions. Moreover, developed regions offer better healthcare infrastructure and are usually early adopters of new therapies. The anti-suicide drugs market in North America and Europe is expected to gain significant traction during the latter half of the forecast period, with the launch of anti-suicidal drug. Increasing healthcare expenditure in emerging economies and high prevalence of suicides in these regions is expected to bring about a paradigm shift in the market. Companies are expected to focus on capitalizing on lucrative opportunities in these regions at the turn of the following decade. This would ensure sustained growth for the market in the foreseeable future.

Global Anti-Suicide Drugs Market Share Analysis (%), by Key Players, 2018

         Anti-Suicide Drugs  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide.

Market Dynamics

Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.

Key features of the study:

  • This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
  • Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics
  • The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Anti-Suicide Drugs Market, By Drug Class:
    • Anti-Depressants and Anti-Anxiety Drugs
    • Anti-Psychotic Drugs
    • NMDA Antagonist
    • Antibiotic Analog
  • Global Anti-Suicide Drugs Market, By Geography:
    • North America
      • U.S.
        • U.S. Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Canada
        • Canada Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
    • Europe
      • U.K.
        • U.K Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Germany
        • Germany Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Italy
        • Italy Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • France
        • France Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Spain
        • Spain Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Russia
        • Russia Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Rest of Europe
        • Rest of Europe Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
    • Asia-Pacific
      • China
        • China Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • India
        • India Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Japan
        • Japan Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • ASEAN
        • ASEAN Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Australia
        • Australia Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • South Korea
        • South Korea Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Rest of Asia Pacific (APAC)
        • Rest of Asia Pacific (APAC) Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
    • Latin America
      • Brazil
        • Brazil Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Mexico
        • Mexico Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Argentina
        • Argentina Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Rest of Latin America
        • Rest of Latin America Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
    • Middle East
      • GCC
        • GCC Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Israel
        • Israel Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Rest of Middle East
        • Rest of Middle East Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
    • Africa
      • North Africa
        • North Africa Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • Central Africa
        • Central Africa Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
      • South Africa
        • South Africa Anti-Suicide Drugs Market, By Drug Class:
          • Anti-Depressant and Anti-Anxiety Drugs
          • Anti-Psychotic Drugs
          • NMDA Antagonist
          • Antibiotic Analog
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • AstraZeneca plc
    • Eli Lilly and Company
    • Allergan plc
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • H. Lundbeck A/S
    • NeuroRx, Inc.
    • Johnson & Johnson

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Drug Class
      • Market Snippet By Geography
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Epidemiology
    • Healthcare Spending
    • PEST Analysis
    • Pipeline Analysis
    • Anti-Suicide Prevention Campaigns and Programs
  4. Global Anti-Suicide Drugs Market, By Drug Class, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, 2016 - 2027
      • Segment Trends
    • Anti-Depressant and Anti-Anxiety Drugs
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2027, (US$ Million)
    • Anti-Psychotic Drugs
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2027, (US$ Million)
    • NMDA Antagonist
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2027, (US$ Million)
    • Antibiotic Analog
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2016 - 2027, (US$ Million)
  5. Global Anti-Suicide Drugs Market, By Geography, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, For Regions, 2016 - 2027
    • North America
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • U.S.
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Canada
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
    • Europe
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • U.K.
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Germany
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Italy
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • France
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Spain
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Russia
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Rest of Europe
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • China
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • India
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Japan
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • ASEAN
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Australia
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • South Korea
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Rest of Asia Pacific
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
    • Latin America
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • Brazil
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Mexico
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Argentina
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Rest of Latin America
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
    • Middle East
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • GCC Countries
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Israel
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Rest of Middle East
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
    • Africa
      • Market Share Analysis, By Country, 2019 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2016 - 2027
        • Northern Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • Central Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
        • South Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Million)
  6. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • Allergan plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • GlaxoSmithkline plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • H. Lundbeck A/S
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • NeuroRx, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Key Developments
        • Market Presence
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 48 market data tables and 44 figures on "Anti-Suicide Drugs Market - Global forecast to 2027”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.